lilly glp 1 injection FDA approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly, Novo Sink on FDA

Routine restriction is not advised in patients without fluid overload [12]

India Issues Urgent GLP-1 Drug Safety Alert The Indian Pharmacopoeia Commission (IPC) has issued a public notice on 14 May calling on doctors, patients, and consumers to closely monitor and report any adverse reactions linked to semaglutide and other GLP-1 receptor agonists including dulaglutide, liraglutide, and tirzepatide

Keywords: GLP-1 receptor agonists, obesity, weight loss, non-diabetic patients, cardiovascular outcomes, cost-effectiveness Introduction Obesity is a chronic disease with high prevalence and associated comorbidities, making it a growing global concern [7] [8]

2021;6(56):eaaz6563